Literature DB >> 758880

Prosthetic aortic valves. Indications for and results of reoperation.

R J Shemin, V A Guadiani, D M Conkle, A G Morrow.   

Abstract

During a 15-year period from January 1962 through December 1976, 42 patients who had undergone a previous aortic valve replacement underwent reoperation. The mean interval between operations was 4.4 years. The indications for reoperation were aortic regurgitation resulting from mechanical malfunction (12 patients), ball variance (15 patients), perivalvular leaks (five patients), prosthetic stenosis (eight patients), anemia (one patient), and recurrent emboli (one patient). The indications were characteristic of a specific valve series. The most common reoperation was aortic valve replacement (29/42), which had a 10.3% operative mortality. Poppet change (10/42) carried a 10% operative mortality and no operative deaths followed suture closure of perivalvular leaks. Eighty-eight percent of patients alive six months after reoperation were New York Heart Association functional class 1 or 2. At last follow-up, 95% of surviving patients were still functional class 1 or 2, with a mean cumulative survival of 4.7 years after reoperation. This experience demonstrates that those patients surviving long enough to undergo reoperation can expect a reasonable operative risk, long-term survival, and excellent clinical improvement.

Entities:  

Mesh:

Year:  1979        PMID: 758880     DOI: 10.1001/archsurg.1979.01370250065013

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  2 in total

1.  Outcomes of reoperative aortic valve replacement after previous sternotomy.

Authors:  Damien J LaPar; Zequan Yang; George J Stukenborg; Benjamin B Peeler; John A Kern; Irving L Kron; Gorav Ailawadi
Journal:  J Thorac Cardiovasc Surg       Date:  2009-12-16       Impact factor: 5.209

Review 2.  Bioengineering aspects of heart valve replacement.

Authors:  F J Schoen; J L Titus; G M Lawrie
Journal:  Ann Biomed Eng       Date:  1982       Impact factor: 3.934

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.